Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Shionogi
Shionogi
One year after Fetroja approval, Shionogi expands label to include difficult-to-treat pneumonia
One year after Fetroja approval, Shionogi expands label to include difficult-to-treat pneumonia
Endpoints
Fetroja
Shionogi
hospital-acquired pneumonia
ventilator-associated bacterial pneumonia
FDA
Flag link:
Biopharma takeovers show quantity, if not quality
Biopharma takeovers show quantity, if not quality
EP Vantage
COVID-19
pandemic
M&A
Novo Nordisk
Corvidia
Gilead Sciences
Pionyr
Alexion
Portola Pharmaceuticals
Menarini
Stemline Therapeutics
Shionogi
Tetra Therapeutics
Flag link:
PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech
PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech
Endpoints
Shionogi
Alzheimer's disease
Tetra Therapeutics
M&A
Flag link:
Shionogi boosts Tetra Alzheimer's deal, nabs buyout option
Shionogi boosts Tetra Alzheimer's deal, nabs buyout option
Fierce Biotech
Shionogi
Tetra Therapeutics
R&D
M&A
Flag link:
Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'
Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'
Endpoints
Roche
Xofluza
Japan
Shionogi
Flu
influenza
Flag link:
After positive panel vote, Shionogi antibiotic scores US approval
After positive panel vote, Shionogi antibiotic scores US approval
Endpoints
Shionogi
antibiotics
FDA
cUTI
UTIs
Fetroja
Flag link:
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Endpoints
Shionogi
FDA
advisory panels
antibiotics
cefiderocol
UTIs
Flag link:
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
Endpoints
Shionogi
FDA
advisory panels
antibiotics
UTIs
cefiderocol
Flag link:
Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Endpoints
Shionogi
antibiotics
FDA
cefiderocol
nosocomial pneumonia
Flag link:
Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug
Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug
Endpoints
Shionogi
Europe
opioid-induced constipation
Symproic
Rizmoic
Flag link:
FDA Approves First New Flu Drug in Nearly 20 Years
FDA Approves First New Flu Drug in Nearly 20 Years
CP Wire
FDA
Xofluza
Flu
Shionogi
Roche
Tamiflu
Flag link:
FDA Approves First New Flu Drug in Nearly 20 Years
Shionogi
Roche
Xofluza
Tamiflu
influenza
Flag link:
Fast-acting flu drug shows strong potential, but clinical trial results also raise concerns
Fast-acting flu drug shows strong potential, but clinical trial results also raise concerns
Stat
clinical trials
Flu
influenza
baloxavir marboxil
Xofluza
Shionogi
Flag link:
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Yahoo/Zacks.com
Shire
Shionogi
ADHD
Japan
Intuniv
Flag link:
FDA hustles through a quick OK for Shionogi’s new thrombocytopenia drug
FDA hustles through a quick OK for Shionogi’s new thrombocytopenia drug
Endpoints
Shionogi
Mulpleta
thrombocytopenia
FDA
Flag link:
Roche’s antiviral hits flu targets in PhIII trial
Roche’s antiviral hits flu targets in PhIII trial
Pharma Times
Roche
baloxavir marboxil
antivirals
Flu
Shionogi
Flag link:
The first single-dose flu drug nod could be FDA’s Christmas present for Roche
The first single-dose flu drug nod could be FDA’s Christmas present for Roche
Fierce Pharma
Roche
Shionogi
Xofluza
Flu
FDA
Flag link:
ViiV Healthcare reports positive results for late-stage HIV trials
ViiV Healthcare reports positive results for late-stage HIV trials
Marketwatch
ViiV Healthcare
GSK
Pfizer
Shionogi
HIV
clinical trials
Dolutegravir
lamivudine
Flag link:
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
Endpoints
SAGE Therapeutics
SAGE-217
Asia
Shionogi
depression
Flag link:
Shionogi’s flu drug wins green light in Japan, but U.S. approval not likely until 2019
Shionogi’s flu drug wins green light in Japan, but U.S. approval not likely until 2019
Fierce Pharma
Japan
Shionogi
Flu
influenza
Xofluza
Flag link:
Pages
1
2
3
next ›
last »